LOS ANGELES (KABC) -- The Food and Drug Administration's approval process is one of the most stringent in the world, but now some experts are questioning newer drugs that go through a quicker review.

The U.S. Food and Drug Administration (FDA) announced a new process called “Rare Disease Evidence Principles” (RDEP), under which eligible drugs and biologics for ultra-rare diseases caused by known ...

The Food and Drug Administration’s glacial pace at reviewing and approving new drugs has an enormous opportunity cost for society in terms of lives lost and illnesses prolonged. For instance, while ...

Many physicians have only a hazy understanding of the FDA's approval process for new drugs and medical devices, a national survey found. Of 509 physicians surveyed, 41% reported a "moderate" or better ...

The clinical trials new drugs and devices must undergo for approval by the U.S. Food and Drug Administration hold the drugs to varying degrees of approval, according to a study published in the ...

In a survey of US physicians, 41% of respondents said they had a moderate or better understanding of the FDA’s processes for drug approval. Many physicians do not have a solid understanding of the US ...